News & Trade Shows

News & Trade shows

Year-End Results 2005 -- September 14, 2005

-- Fiscal Year EPS $0.03 per share --

NEWPORT BEACH, Calif., September 14, 2005 – Biomerica, Inc. (OTCBB: BMRA) today announced its financial results for its fiscal year ended May 31, 2005.   

Biomerica reported consolidated net sales for fiscal year 2005 of $9,273,980 compared to $9,168,833 in fiscal 2004, an increase of  $105,147 or 1.1%.   Consolidated net income was $162,259, or income of  $0.03 per share, in fiscal 2005, as compared to a consolidated net loss of $223,201, or a loss of $0.04 per share, in fiscal 2004.  Operating profit for the fiscal year from the diagnostic products group was approximately $70,000 compared to an operating loss of approximately $315,500 for the prior fiscal year.  

“We are pleased to report a modest fiscal year profit for our diagnostic products group.  Biomerica’s operating profit from diagnostic products, net of intercompany adjustments, during the fourth quarter ended May 2005 was approximately $65,106, up from a loss of approximately $65,559 during the previous year,” stated Zackary Irani, Biomerica CEO.   “We are continuing to gain distribution and move forward with planned new product introductions.  In addition, we expect that the first quarter of fiscal 2006 compared to the same quarter in fiscal 2005 will continue to show significant improvements in our financial performance.”

About Biomerica (OTBB: BMRA)
Biomerica, Inc. ( is a global medical technology company, based in Newport Beach, CA.  The Company’s diagnostics division manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, slated new product releases, expected sales, expansion, expected orders, leading market positions, financial performance,  anticipated future revenues or production volume of the company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.